Skip to main content
logo
Adial Pharmaceuticals, Inc. (ADIL)
NASDAQ: ADIL · Real-Time Price · USD
6.00
0.00 (0.08%)
Sep 11, 2026, 4:00 PM EDT - Market closed

Adial Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
9.485.185.065.628.919.3
Research & Development
2.012.623.231.271.958.4
Operating Expenses
11.497.88.286.8910.8617.69
Operating Income
-11.49-7.8-8.28-6.89-10.86-17.69
Interest Expense
-2.07-----
Interest & Investment Income
0.20.150.180.070.060.01
Earnings From Equity Investments
-0.48-0.49-0.55-0.19--
Other Non Operating Income (Expenses)
8.280.16-0.080.01-0.02
EBT Excluding Unusual Items
-5.56-7.98-8.73-7-10.8-17.67
Merger & Restructuring Charges
------0.05
Asset Writedown
------1.55
Other Unusual Items
-6.05--4.46---0.25
Pretax Income
-57.8-7.98-13.2-7-10.8-19.52
Income Tax Expense
------0.09
Earnings From Continuing Operations
-57.8-7.98-13.2-7-10.8-19.42
Earnings From Discontinued Operations
---1.88-1.94-
Net Income
-57.8-7.98-13.2-5.12-12.73-19.42
Net Income to Common
-57.8-7.98-13.2-5.12-12.73-19.42
Net Income Growth
------
Shares Outstanding (Basic)
310000
Shares Outstanding (Diluted)
310000
Shares Change
791.51%244.55%240.54%42.25%34.69%49.15%
EPS (Basic)
-22.01-11.93-68.01-89.91-317.81-653.06
EPS (Diluted)
-22.01-11.93-68.01-89.91-317.81-653.06
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-11.13-6.49-6.92-6.81-11.19-12.01
Free Cash Flow Per Share
-4.24-9.71-35.67-119.45-279.23-403.94
EBITDA
-11.49-7.8-8.28-6.89-10.86-17.69
D&A For EBITDA
000000.01
EBIT
-11.49-7.8-8.28-6.89-10.86-17.69
SEC Filings: 10-K · 10-Q